fda approved semaglutide approves higher dose of Wegovy to increase patient weight loss Ozempic® GLP for Weight Loss

The scientists have finished a 26-week phase II clinical study and revealed that semaglutide showed statistically significant better glycemic control than a placebo

Long-term safety, cardiovascular outcomes, and real-world tolerability are still under evaluation in ongoing Phase 3 programs

Wash your hands thoroughly before handling any supplies

Propranolol is a non-selective beta-blocker, meaning it blocks both beta-1 (heart) and beta-2 (airway and vascular) receptors, which is why it poses a greater risk of blunting adrenaline's bronchodilatory effect and worsening bronchospasm compared to cardioselective beta-blockers such as bisoprolol or atenolol